WO2001085709A3 - New compounds having anticancer activity: process for their preparation and pharmaceutical compositions containing them - Google Patents
New compounds having anticancer activity: process for their preparation and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- WO2001085709A3 WO2001085709A3 PCT/IB2001/000737 IB0100737W WO0185709A3 WO 2001085709 A3 WO2001085709 A3 WO 2001085709A3 IB 0100737 W IB0100737 W IB 0100737W WO 0185709 A3 WO0185709 A3 WO 0185709A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- pharmaceutical compositions
- compositions containing
- andrographolide
- new compounds
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical class C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000000078 anti-malarial effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000003430 antimalarial agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002443 hepatoprotective effect Effects 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001256568A AU2001256568A1 (en) | 2000-05-05 | 2001-05-02 | New compounds having anticancer activity: process for their preparation and pharmaceutical compositions containing them |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN353/MAS/2000 | 2000-05-05 | ||
IN435MA2000 | 2000-06-08 | ||
IN435/MAS/2000 | 2000-06-08 | ||
IN353MA2000 | 2000-06-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001085709A2 WO2001085709A2 (en) | 2001-11-15 |
WO2001085709A3 true WO2001085709A3 (en) | 2002-05-30 |
Family
ID=26324891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2001/000737 WO2001085709A2 (en) | 2000-05-05 | 2001-05-02 | New compounds having anticancer activity: process for their preparation and pharmaceutical compositions containing them |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001256568A1 (en) |
WO (1) | WO2001085709A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106800551A (en) * | 2015-11-26 | 2017-06-06 | 南京明德新药研发股份有限公司 | Andrographolide changes structure compound |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7902359B2 (en) | 2006-12-11 | 2011-03-08 | Hutchison Medipharma Enterprises Limited | Decahydronaphthalene compounds |
CN101591686B (en) * | 2009-06-23 | 2011-08-31 | 南京农业大学 | Method for preparing andrographolide esterfied derivatives through biocatalysis |
CN103145665B (en) * | 2012-04-12 | 2014-12-31 | 江西青峰药业有限公司 | 17-hydro-9-dehydro-14,17-cyclo-andrographolide-19-sulphate and its preparation method and use in drug preparation |
WO2017088738A1 (en) * | 2015-11-26 | 2017-06-01 | 南京明德新药研发股份有限公司 | Modified compound of andrographolide |
CN105541766B (en) * | 2015-12-16 | 2018-08-24 | 四川理工学院 | The andrographolidume derivative of a kind of sulfur-bearing, its pharmaceutical composition, synthetic method and purposes |
CN108484543B (en) * | 2018-03-23 | 2020-11-03 | 海南长春花药业有限公司 | Preparation method of potassium dehydroandrographolide succinate or potassium dehydroandrographolide succinate |
CN109912583A (en) * | 2019-04-03 | 2019-06-21 | 四川轻化工大学 | Sulfur-containing andrographolide derivatives cyclized at 3, 19-position, pharmaceutical composition, synthetic method and application thereof |
CN112645937B (en) * | 2020-12-28 | 2022-05-31 | 深圳湾实验室 | Azaspirocycle, polycyclic andrographolide compound and preparation method thereof, pharmaceutical composition and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6388124A (en) * | 1986-09-30 | 1988-04-19 | Toyo Jozo Co Ltd | Antitumor agent |
WO1996017605A1 (en) * | 1994-12-06 | 1996-06-13 | Paracelsian, Inc. | Use of andrographolide compounds to treat or prevent pathogenicity of diseases |
WO1998030213A2 (en) * | 1997-01-08 | 1998-07-16 | Paracelsian, Inc. | Use of the ah receptor and ah receptor ligands to treat or prevent the cytopathicity of viral infection |
-
2001
- 2001-05-02 AU AU2001256568A patent/AU2001256568A1/en not_active Abandoned
- 2001-05-02 WO PCT/IB2001/000737 patent/WO2001085709A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6388124A (en) * | 1986-09-30 | 1988-04-19 | Toyo Jozo Co Ltd | Antitumor agent |
WO1996017605A1 (en) * | 1994-12-06 | 1996-06-13 | Paracelsian, Inc. | Use of andrographolide compounds to treat or prevent pathogenicity of diseases |
WO1998030213A2 (en) * | 1997-01-08 | 1998-07-16 | Paracelsian, Inc. | Use of the ah receptor and ah receptor ligands to treat or prevent the cytopathicity of viral infection |
Non-Patent Citations (2)
Title |
---|
LIU XUE-GAO ET AL: "ANTIFERTILITY EFFECT OF DEHYDROANDROGRAPHOLIDE DERIVATIVES ON MICE AND RATS", ADVANCES IN CONTRACEPTIVE DELIVERY SYSTEMS, REPRODUCTIVE HEALTH CENTER, KAIWAH ISLAND, SC, US, vol. 111, no. 4, 1987, pages 329 - 336, XP000568141, ISSN: 1012-8689 * |
TAKAKUNI MATSUDA ET AL: "CELL DIFFERENTIATION-INDUCING DITERPENES FROM ANDROGRAPHIS PANICULATA NEES", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 42, no. 6, 1 June 1994 (1994-06-01), pages 1216 - 1225, XP000567717, ISSN: 0009-2363 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106800551A (en) * | 2015-11-26 | 2017-06-06 | 南京明德新药研发股份有限公司 | Andrographolide changes structure compound |
Also Published As
Publication number | Publication date |
---|---|
AU2001256568A1 (en) | 2001-11-20 |
WO2001085709A2 (en) | 2001-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02007513A (en) | Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them. | |
IL148103A0 (en) | Novel dicarboxylic acid derivatives with pharmaceutical properties | |
WO2001019776A3 (en) | Novel derivatives of dicarboxylic acid having pharmaceutical properties | |
CA2374247A1 (en) | Heterocyclic derivatives useful as anticancer agents | |
MY128659A (en) | Novel aminodicarboxylic acid derivatives having pharmaceutical properties | |
CA2398620A1 (en) | Pyrazine derivatives, pharmaceutical compositions containing them, and intermediates therefor | |
HK1060117A1 (en) | Taxol enhancer compounds | |
CA2333703A1 (en) | Isothiazole derivatives useful as anticancer agents | |
ATE264337T1 (en) | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THESE AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION | |
YU11699A (en) | 6-substituted ketolydes having a bactericidal impact, procedures for the production thereof and their pharmaceutical preparations | |
PT1308439E (en) | Proline derivatives and use thereof as drugs | |
WO1999008501A3 (en) | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | |
HUT62893A (en) | Process for producing substituted pyrimidine derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
WO2002051819A3 (en) | Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them | |
NO20060650L (en) | Quinazoline derivatives as angiogenesis inhibitors | |
WO2001085709A3 (en) | New compounds having anticancer activity: process for their preparation and pharmaceutical compositions containing them | |
CA2469592A1 (en) | Hiv integrase inhibitors | |
MX344556B (en) | 5-ht1a. | |
WO2000041469A3 (en) | β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS | |
CA2331297A1 (en) | Hygromycin a derivatives | |
SG146627A1 (en) | Imidazole derivatives | |
DE60234024D1 (en) | NEW RETINOID DERIVATIVES AND A PHARMACEUTICAL ANTI-CANCER COMPOSITION CONTAINING THESE COMPOUNDS | |
IL159521A0 (en) | Tricyclic pyridines for use in treatment of conditions mediated by crf | |
MXPA04002784A (en) | Pharmaceutically acceptable salts of 20(s)-camptothecins. | |
HRP20010845A9 (en) | Cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |